GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » FCF Yield %

TriSalus Life Sciences (TriSalus Life Sciences) FCF Yield % : -9.93 (As of May. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, TriSalus Life Sciences's Trailing 12-Month Free Cash Flow is $-29.39 Mil, and Market Cap is $295.87 Mil. Therefore, TriSalus Life Sciences's FCF Yield % for today is -9.93%.

The historical rank and industry rank for TriSalus Life Sciences's FCF Yield % or its related term are showing as below:

TLSI' s FCF Yield % Range Over the Past 10 Years
Min: -41.61   Med: -12.55   Max: -6.28
Current: -9.93

During the past 3 years, the highest FCF Yield % of TriSalus Life Sciences was -6.28%. The lowest was -41.61%. And the median was -12.55%.

TLSI's FCF Yield % is ranked worse than
65.28% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: -2.63 vs TLSI: -9.93

TriSalus Life Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was -166.91%.

TriSalus Life Sciences FCF Yield % Historical Data

The historical data trend for TriSalus Life Sciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences FCF Yield % Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
FCF Yield %
- - -22.92

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial - - - - -17.11

Competitive Comparison of TriSalus Life Sciences's FCF Yield %

For the Medical Devices subindustry, TriSalus Life Sciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TriSalus Life Sciences's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's FCF Yield % falls into.


TriSalus Life Sciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

TriSalus Life Sciences's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-51.166 / 223.19154
=-22.92%

TriSalus Life Sciences's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-9.549 * 4 / 223.19154
=-17.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

TriSalus Life Sciences FCF Yield % Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences (TriSalus Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » FCF Yield %
Comparable Companies
INGN HYBT HYPR CLPT ELMD TELA MGRM AXDX APYX NSPR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
6272 W. 91st Avenue, Westminster, CO, USA, 80031
Website
https://trisaluslifesci.com
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Executives
Jodi Devlin officer: President, Therapeutics C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih officer: President, Device Technology C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox officer: Chief Scientific & Manufact. C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks director C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
George Kelly Martin director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens officer: Chief Regulatory Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak officer: Sr.VP, Corp. Dev. & Strategy C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mary T Szela director, officer: CEO and President 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Anil K. Singhal director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy director, officer: Chief Financial Officer C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz officer: Chief Medical Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom director, 10 percent owner 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius 10 percent owner BOX 984, BORAS V7 SE-501 10